Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
CTXR closed unchanged on Thursday, July 19, 2018, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
|Weak or Absent||Down||Up||Down|
|See historical CTXR trend table...|
|Date||Alert Name||Type||% Chg|
|Jul 19||50 DMA Support||Bullish||0.00%|
|Jul 19||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Jul 19||Calm After Storm||Range Contraction||0.00%|
|Jul 19||NR7||Range Contraction||0.00%|
|Jul 19||Inside Day||Range Contraction||0.00%|
|Jul 19||Wide Bands||Range Expansion||0.00%|
|Jul 18||50 DMA Support||Bullish||0.00%|
|Jul 18||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Jul 18||Wide Bands||Range Expansion||0.00%|
|Jul 18||Down 3 Days in a Row||Weakness||0.00%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CTXR news...
|52 Week High||5.49|
|52 Week Low||2.08|
|200-Day Moving Average||3.3874|
|50-Day Moving Average||2.5743|
|20-Day Moving Average||2.489|
|10-Day Moving Average||2.6505|
|Average True Range||0.2175|
|Chandelier Exit (Long, 3 ATRs )||2.4975|
|Chandelier Exit (Short, 3 ATRs )||2.7325|
|Upper Bollinger Band||2.9586|
|Lower Bollinger Band||2.0194|
|Percent B (%b)||0.65|
|MACD Signal Line||0.0097|
|Market Cap||21.7 Million|
|Num Shares||8.25 Million|
|Price-to-Earnings (P/E) Ratio||-1.33|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||2.80|
|Resistance 3 (R3)||2.78||2.71||2.77|
|Resistance 2 (R2)||2.71||2.67||2.72||2.76|
|Resistance 1 (R1)||2.67||2.64||2.69||2.69||2.75|
|Support 1 (S1)||2.56||2.56||2.58||2.58||2.51|
|Support 2 (S2)||2.49||2.53||2.50||2.50|
|Support 3 (S3)||2.45||2.49||2.49|
|Support 4 (S4)||2.47|